May 2006
Volume 47, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2006
Effect of MMP Inhibitor Ilomastat on Tissue Contraction Mediated by Different Fibroblasts
Author Affiliations & Notes
  • B.M. Martin
    Institute of Ophthalmology and Moorfields Eye Hospital, London, United Kingdom
    Cell Biology Division,
    Ocular Repair and Regeneration Biology Unit,
  • P.T. Khaw
    Institute of Ophthalmology and Moorfields Eye Hospital, London, United Kingdom
    Ocular Repair and Regeneration Biology Unit,
  • M. Bailly
    Institute of Ophthalmology and Moorfields Eye Hospital, London, United Kingdom
    Cell Biology Division,
    Ocular Repair and Regeneration Biology Unit,
  • Footnotes
    Commercial Relationships  B.M. Martin, None; P.T. Khaw, None; M. Bailly, None.
  • Footnotes
    Support  Fundacion Ramon Areces (Spanish Society), Medical Research Council, Royal Society, Wellcome Trust
Investigative Ophthalmology & Visual Science May 2006, Vol.47, 2621. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      B.M. Martin, P.T. Khaw, M. Bailly; Effect of MMP Inhibitor Ilomastat on Tissue Contraction Mediated by Different Fibroblasts . Invest. Ophthalmol. Vis. Sci. 2006;47(13):2621.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Broad spectrum MMP inhibitor Ilomastast has proven efficient in preventing ocular tissue scarring after experimental glaucoma filtration surgery. The purpose of this study is to characterise its biological mode of action in a standard in vitro contraction.

Methods: : Free–floating fibroblast–populated type I collagen matrices were prepared with Scleral, Tenon's capsule and NIH3T3 fibroblasts. Gel contraction induced with foetal calf serum in presence or absence of Ilomastat was monitored macroscopically using digital photography. The biological behaviour of the cells and their interaction with the collagen matrix was analysed using confocal reflection microscopy. OpenLab and Volocity software packages were used to analyse the 3 and 4D reconstructed image series. Cell division and matrix metalloproteinase activity were measured by cell counts and fluorimetric assay respectively.

Results: : While similar end point contraction (70–90% of original volume) was obtained by varying the number of cells in the gels, the different types of fibroblasts display distinct behaviour and interaction with the matrix during contraction. The Tenon's did not divide in the matrix but efficiently pulled collagen fibers. Scleral cells divided significantly over 7 days, but were poorly efficient in pulling matrix fibers, while 3T3 cell displayed moderate behaviour for both cell division and matrix displacement. Conversely, collagen degradation around the cells was more pronounced with the scleral fibroblasts. The inhibitory effect of Ilomastat on contraction was more pronounced on Tenon's fibroblasts than 3T3 or scleral fibroblasts, despite Ilomastat clearly inhibiting on cell division in the latter ones. Ilomastat decreased the MMP activity released in the gels after serum stimulation of scleral cells, but increased membrane–bound MMP activity over 7 days.

Conclusions: : We propose that different types of cell use different behavioural combinations to achieve matrix contraction. Tenon's fibroblasts are extremely efficient at pulling collagen fibers, resulting in active contracting force. Scleral fibroblasts are poorly efficient at pulling the matrix but can increase their overall contracting force through cell division. These cells are poorly inhibited in their contraction ability by Ilomastat, despite the MMP inhibitor significantly blocking cell division and soluble MMP production. Our data suggest that successful modulation of tissue scarring in the eye by MMP inhibitors will depend on the type of tissue affected.

Keywords: microscopy: confocal/tunneling • enzymes/enzyme inhibitors • wound healing 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×